Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Storspråkmodellbasert følelsesmessig håndtering for pasienter med brystkreft (EMBRACE)

20. september 2026 oppdatert av: Nanfang Hospital, Southern Medical University

Emosjonshåndtering basert på store språkmodeller for pasienter med brystkreft: En multi-center, randomisert, kontrollert studie

This study (study type: randomized controlled trial) aims to evaluate whether a large language model-based precision emotional management intervention can improve health-related quality of life among patients with primary breast cancer. The study will enroll adult women (≥18 years old) with pathologically confirmed primary breast cancer who own a smartphone, regularly use social media platforms, and have an expected survival of at least 6 months.

The primary questions this study seeks to answer are:

  1. Does the intervention improve health-related quality of life (EORTC QLQ-C30 summary score) at 6 months post-intervention?
  2. Does the intervention reduce anxiety, depression, cancer-related symptom burden, and unplanned hospitalizations in this population? With a control group in place, researchers will compare changes in health-related quality of life, anxiety, depression, and cancer-related symptom burden between the intervention group (receiving digital precision emotional management plus usual care) and the control group (receiving usual care only) to determine whether the intervention leads to significant improvements in these outcomes.

Participants will be required to:

  1. Complete baseline and follow-up assessments of health-related quality of life, anxiety, depression, and cancer-related symptoms at 1, 3, and 6 months post-randomization.
  2. For those in the intervention group, use the digital precision emotional management system autonomously for 6 months, including submitting self-reported emotional diaries and completing biweekly skill translation assessments.
  3. For all participants, report any adverse events and unplanned hospitalizations during the study period.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

440

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Guangzhou, Kina
        • Nanfang Hospital, Southern Medical University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Provision of written informed consent;
  • Aged 18 years or over;
  • Histopathologically confirmed primary breast cancer;
  • Ownership of a smartphone and ability to independently operate the intervention system;
  • Regular use (at least three times per week) of one or more third-party social media platforms (e.g., Weibo, Douyin, or Xiaohongshu);
  • Clear consciousness, basic reading and writing ability (equivalent to primary education or above), and adequate communication capacity;
  • An estimated life expectancy of six months or longer, as assessed by the treating physician.

Exclusion Criteria:

  • Diagnosed with cognitive impairment or psychiatric disorders that substantially interfere with assessment or participation;
  • Pregnancy or lactation;
  • Presence of other malignant tumours, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix, or severe organic disease (including cardiac, hepatic, or renal insufficiency);
  • Substance abuse (including alcohol or drug dependence) or current suicidal ideation;
  • Concurrent participation in other clinical trials or interventional studies that may interfere with outcome evaluation.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: APP Managemengt Group

This intervention is a digital precision emotional management system based on a large language model, classified as a behavioral intervention. The system automatically analyzes text data from social media and in-app platforms to detect six basic emotions (joy, anger, sadness, fear, disgust, and surprise) in near real-time, and generates personalized patient labels by integrating patients' physical symptoms. Leveraging an evidence-based knowledge base, the system delivers tailored strategies for emotion regulation and symptom management, including emotion management techniques, symptom relief recommendations, and health education content. Patients in the intervention group autonomously use this system for 6 months in addition to receiving usual care, and complete biweekly skill translation assessments to facilitate the application of intervention skills in daily life.

This intervention is a digital precision emotional management system based on a large language model, classified as a behavioral intervention. The system automatically analyzes text data from social media and in-app platforms to detect six basic emotions (joy, anger, sadness, fear, disgust, and surprise) in near real-time, and generates personalized patient labels by integrating patients' physical symptoms. Leveraging an evidence-based knowledge base, the system delivers tailored strategies for emotion regulation and symptom management, including emotion management techniques, symptom relief recommendations, and health education content. Patients in the intervention group autonomously use this system for 6 months in addition to receiving usual care, and complete biweekly skill translation assessments to facilitate the application of intervention skills in daily life.

Aktiv komparator: usual care

Participants allocated to the control group receive usual emotional and symptom management for breast cancer, with no exposure to the digital intervention system. Standard care includes routine follow-up examinations, symptom management, psychological support, health education, and guidance on wound care, drainage tube management, diet, rest, and physical activity. All care is delivered in accordance with established clinical nursing procedures at the treating hospital.

During follow-up, participants experiencing severe psychological distress (e.g. suicidal ideation) are referred to psychiatric services in line with standard clinical practice. After completion of the trial, control-group participants are offered the option to access the intervention system voluntarily.

Participants allocated to the control group receive usual emotional and symptom management for breast cancer, with no exposure to the digital intervention system. Standard care includes routine follow-up examinations, symptom management, psychological support, health education, and guidance on wound care, drainage tube management, diet, rest, and physical activity. All care is delivered in accordance with established clinical nursing procedures at the treating hospital.

During follow-up, participants experiencing severe psychological distress (e.g. suicidal ideation) are referred to psychiatric services in line with standard clinical practice. After completion of the trial, control-group participants are offered the option to access the intervention system voluntarily.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Health-related quality of life (EORTC QLQ-C30 summary score)
Tidsramme: Baseline and at 1st, 3rd and 6th months after intervention

In this study, the EORTC QLQ-C30 Summary Score is used as the primary analysis endpoint, and assessments are conducted using the Chinese version of the EORTC QLQ-C30 questionnaire.

The EORTC QLQ-C30 Summary Score is calculated using the "13-domain mean method." Raw scores are first obtained from five functional scales and eight symptom scales, with all scores transformed to a 0-100 scale. All symptom scale scores are then reverse-scored, as higher original symptom scores indicate greater symptom burden; after transformation, higher scores uniformly indicate better outcomes, corresponding to milder symptoms. The arithmetic mean of the transformed scores across the 13 scales is subsequently calculated to generate the Summary Score, which remains on a 0-100 scale, with higher scores indicating better overall health-related quality of life.

Baseline and at 1st, 3rd and 6th months after intervention

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Health-related quality of life
Tidsramme: Baseline and at 1st, 3rd and 6th months after intervention

The EORTC QLQ-C30 questionnaire comprises 15 dimensions, including five functional domains (physical, role, emotional, cognitive, and social functioning), three symptom domains (fatigue, pain, and nausea/vomiting), one Global Health Status/Quality of Life domain, and six single-item symptom scales (e.g., dyspnea, insomnia). Scoring is performed by first calculating the mean of the raw scores for each domain or item, which is then linearly transformed into a standardized 0-100 score using the formula (mean raw score-1)/range of response options×100. For the functional domains and the Global Health Status/Quality of Life domain, higher scores indicate better functioning or quality of life (positive scoring), whereas for the symptom domains, higher scores indicate greater symptom severity and poorer health status (negative scoring).

Baseline and at 1st, 3rd and 6th months after intervention
Anxiety
Tidsramme: Baseline and at 1st, 3rd and 6th months after intervention

The Generalized Anxiety Disorder Scale (GAD-7) was used, consisting of 7 items, to assess the degree to which patients were troubled by anxiety-related symptoms such as tension, worry, and difficulty in relaxation over the past 2 weeks; the total score of this scale ranges from 0 to 21, with higher scores indicating more significant emotional symptoms.

Baseline and at 1st, 3rd and 6th months after intervention
Depression
Tidsramme: Baseline and at 1st, 3rd and 6th months after intervention

The Patient Health Questionnaire-9 (PHQ-9) was used, which consists of 9 items and has a total score ranging from 0 to 27. The higher the score, the more significant the emotional symptoms are.

Baseline and at 1st, 3rd and 6th months after intervention
Cancer-related symptom burden
Tidsramme: Baseline and at 1st, 3rd and 6th months after intervention

Each symptom score is calculated as the mean of frequency, severity, and distress ratings (range 0-4), with absent symptoms scored as zero. Higher MSAS scores indicate greater symptom burden.

Baseline and at 1st, 3rd and 6th months after intervention
Unplanned hospitalization rate
Tidsramme: Within 7 days after the intervention ended after 6 months

The unplanned hospitalization rate is defined as the ratio of the total number of unplanned hospitalization events to the total number of person-months in the study cohort, and is expressed as the number of events per person-month. Unplanned hospitalization is defined as admission via emergency or urgent care. Planned hospitalizations for the purposes of chemotherapy or radiotherapy (ICD-9 codes: V58.0, V58.1, V58.11, V58.12) and rehabilitation (ICD-9 codes: V57.xx) are excluded. When the admission type is unknown, hospitalizations with emergency department charges greater than zero are classified as unplanned hospitalizations; otherwise, they are categorized as other hospitalizations.

Within 7 days after the intervention ended after 6 months
Time to first unplanned hospitalization
Tidsramme: Within 7 days after the intervention ended after 6 months

Time from the date of randomization to the occurrence of the first unplanned hospitalization event.

Within 7 days after the intervention ended after 6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. mars 2026

Primær fullføring (Antatt)

30. november 2026

Studiet fullført (Antatt)

20. desember 2026

Datoer for studieregistrering

Først innsendt

23. februar 2026

Først innsendt som oppfylte QC-kriteriene

27. februar 2026

Først lagt ut (Faktiske)

5. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • NFEC-2026-035

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data that underlie the results reported in the primary publication will be made available to qualified researchers upon reasonable request, subject to applicable ethical and institutional requirements, data protection regulations, and approval of a methodologically sound research proposal. Requests will be considered provided that the proposed use does not conflict with ongoing or planned analyses by the original investigators. A data use agreement may be required. The study protocol and statistical analysis plan are publicly available through the ClinicalTrials.gov registration.

IPD-delingstidsramme

Data will become available upon publication of the primary results and will remain available for 5 years thereafter.

Tilgangskriterier for IPD-deling

Data will be shared with qualified researchers who submit a methodologically sound research proposal for scientifically justified research purposes. Requests will be reviewed by the study investigators or an appropriate institutional review body, as applicable, and access will be subject to applicable ethical, institutional, and data protection requirements. A data use agreement may be required before access is granted. Requests should be directed to the corresponding author using an institutional email address.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere